BNP Paribas Fortis Bank 0.75% 01may2025 (BE2141211331) News

Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above

– FDA grants traditional approval to ELEVIDYS for ambulatory Duchenne patients – FDA grants accelerated approval to ELEVIDYS for non-ambulatory...

Adobe Soars 15% Pre-Market; Visa and Mastercard Encounter Hurdles in $30 Billion Agreement, and More

Adobe (NASDAQ:ADBE) – Adobe exceeded expectations in the last quarter with revenue of $5.31 billion...

Form 8-K - Current report

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2024 (the...

Sarepta Therapeutics Set to Join S&P MidCap 400

Sarepta Therapeutics Set to Join S&P MidCap 400 PR Newswire NEW YORK, May 29, 2024 NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health

– TIME recognizes Dr. Mendell’s decades-long contributions in the treatment of neuromuscular disease and the advancement of gene therapy...

Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments

Net product revenues for the first quarter 2024 totaled $359.5 million, a 55% increase over the same quarter of the prior year ELEVIDYS net...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 30, 2024...

Sarepta Therapeutics to Announce First Quarter 2024 Financial Results

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2024...

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities